Volitionrx (VNRX) Common Equity (2011 - 2025)

Volitionrx (VNRX) has 12 years of Common Equity data on file, last reported at -$35.6 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity fell 36.33% year-over-year to -$35.6 million; the trailing twelve-month figure through Dec 2025 stood at -$35.6 million (down 36.33% YoY), and the FY2025 full-year result was -$35.6 million, down 36.33% from the prior year.
• Common Equity for Q4 2025 stood at -$35.6 million, down from -$34.6 million in the prior quarter.
• Across five years, Common Equity topped out at $31.2 million in Q1 2021 and bottomed at -$35.6 million in Q4 2025.
• The 5-year median for Common Equity is -$3.1 million (2022), against an average of -$5.9 million.
• The widest annual swing landed in 2021, when Common Equity jumped 239.27%; it then sank 694.03% in 2024.
• A 5-year view of Common Equity shows it stood at $17.7 million in 2021, then sank by 117.64% to -$3.1 million in 2022, then slumped by 178.62% to -$8.7 million in 2023, then plunged by 199.67% to -$26.1 million in 2024, then sank by 36.33% to -$35.6 million in 2025.
• The last three Common Equity figures came in at -$35.6 million (Q4 2025), -$34.6 million (Q3 2025), and -$33.1 million (Q2 2025), per Business Quant data.

Peer Comparison